Advanced search
1 file | 1.86 MB Add to list

Three decades of messenger RNA vaccine development

Rein Verbeke (UGent) , Ine Lentacker (UGent) , Stefaan De Smedt (UGent) and Heleen Dewitte (UGent)
(2019) NANO TODAY. 28.
Author
Organization
Keywords
mRNA vaccine, Lipid nanoparticle, Cancer immunotherapy, Type I IFN, Checkpoint inhibition, T-CELL RESPONSES, LIPID NANOPARTICLE FORMULATIONS, PERIPHERAL LYMPHOID ORGANS, ANTIGEN-PRESENTING CELLS, DENDRITIC CELLS, IN-VIVO, IMMUNE-RESPONSES, CANCER-IMMUNOTHERAPY, DIRECT-INJECTION, CAP-ANALOGS

Downloads

  • Verbeke. et al. Three decades of mRNA vaccine development.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 1.86 MB

Citation

Please use this url to cite or link to this publication:

MLA
Verbeke, Rein, et al. “Three Decades of Messenger RNA Vaccine Development.” NANO TODAY, vol. 28, 2019, doi:10.1016/j.nantod.2019.100766.
APA
Verbeke, R., Lentacker, I., De Smedt, S., & Dewitte, H. (2019). Three decades of messenger RNA vaccine development. NANO TODAY, 28. https://doi.org/10.1016/j.nantod.2019.100766
Chicago author-date
Verbeke, Rein, Ine Lentacker, Stefaan De Smedt, and Heleen Dewitte. 2019. “Three Decades of Messenger RNA Vaccine Development.” NANO TODAY 28. https://doi.org/10.1016/j.nantod.2019.100766.
Chicago author-date (all authors)
Verbeke, Rein, Ine Lentacker, Stefaan De Smedt, and Heleen Dewitte. 2019. “Three Decades of Messenger RNA Vaccine Development.” NANO TODAY 28. doi:10.1016/j.nantod.2019.100766.
Vancouver
1.
Verbeke R, Lentacker I, De Smedt S, Dewitte H. Three decades of messenger RNA vaccine development. NANO TODAY. 2019;28.
IEEE
[1]
R. Verbeke, I. Lentacker, S. De Smedt, and H. Dewitte, “Three decades of messenger RNA vaccine development,” NANO TODAY, vol. 28, 2019.
@article{8628303,
  articleno    = {{100766}},
  author       = {{Verbeke, Rein and Lentacker, Ine and De Smedt, Stefaan and Dewitte, Heleen}},
  issn         = {{1748-0132}},
  journal      = {{NANO TODAY}},
  keywords     = {{mRNA vaccine,Lipid nanoparticle,Cancer immunotherapy,Type I IFN,Checkpoint inhibition,T-CELL RESPONSES,LIPID NANOPARTICLE FORMULATIONS,PERIPHERAL LYMPHOID ORGANS,ANTIGEN-PRESENTING CELLS,DENDRITIC CELLS,IN-VIVO,IMMUNE-RESPONSES,CANCER-IMMUNOTHERAPY,DIRECT-INJECTION,CAP-ANALOGS}},
  language     = {{eng}},
  pages        = {{17}},
  title        = {{Three decades of messenger RNA vaccine development}},
  url          = {{http://dx.doi.org/10.1016/j.nantod.2019.100766}},
  volume       = {{28}},
  year         = {{2019}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: